Modig Berndt sold $80K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,292 shares of Pharvaris N.V. (PHVS) at $34.77 on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Aug 18, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 4:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but without additional company-specific catalysts (earnings, trial results, guidance, deals), the incremental decision value is limited.

02

Market read

A disclosed CEO 10b5-1 sale is new information, but it is typically not a strong standalone catalyst.

03

What to watch

The article does not state whether other insiders sold, whether there were concurrent buys, or whether the company had any contemporaneous news that could contextualize the transaction.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-18, covering sale dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V., reporting a CEO open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Form 4 shows CEO Modig Berndt sold 2,292 shares of Pharvaris N.V. at $34.7669 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and the article provides no accompanying operational or financial catalyst.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide regulatory or clinical update.

None indicated.

None indicated.

Counterpoint

10b5-1 sales are often mechanical and may not reflect bearish fundamentals; the sale could be for diversification or liquidity needs.

Key entities

  • PHVS

    Pharvaris N.V., subject of the Form 4 insider sale disclosure.

  • Modig Berndt

    CEO and director who sold 2,292 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.